Fig. 5
From: A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer
pAXLxCD3ε in vivo activity. A Schematic representation of in vivo EOC xenograft model. B Percentage (%) of malignant cells in the ascites of NSG mice treated with pAXLxCD3ε 0.1 mg/kg compared to mice treated with vehicle alone. C Representative FACS dot plot of T cell engraftment evaluated on the day of sacrifice on (intracardiac) IC blood sample of treated mice. D Tumor volume curve of mice treated with pAXLxCD3ε 0.1 mg/kg as compared to vehicle alone E Survival curves (Kaplan- Meier) of mice treated with pAXLxCD3ε BTCE 0.1 mg/kg as compared to vehicle alone